SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has approved the ...
If you or someone you know has a condition called chronic spontaneous urticaria (CSU), you may have heard about Xolair. In 2014, Xolair became the first medicine to be approved for treating this ...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has accepted, under ...
Detailed results from the NIH-sponsored Phase III OUtMATCH study showed treatment with Xolair increased the amount of peanuts, tree nuts, egg, milk and wheat that people as young as 1 year consumed ...
This is an archived article and the information in the article may be outdated. Please look at the time stamp on the story to see when it was last updated. A medication used to treat asthma can now be ...
Xolair (omalizumab) is a prescription drug that works by blocking IgE to help reduce inflammation. Your response to this drug may vary based on your medical history and diagnosis. IgE is a protein ...
The US Food and Drug Administration (FDA) has approved omalizumab injection (Xolair, Genentech) for children aged 1 year or older and adults to reduce immunoglobulin E─mediated severe allergy to ...
A new study finds that the asthma medication Xolair may substantially reduce severe allergic reactions in people who have multiple food allergies and are accidentally exposed to those foods. Data ...
Findings showed equivalent efficacy in change from baseline in weekly itch severity score between omalizumab-igec 300mg and Xolair 300mg. The Food and Drug Administration (FDA) has approved Omlyclo ® ...
Please provide your email address to receive an email when new articles are posted on . WASHINGTON — Omalizumab increased thresholds for reacting to peanut and other common allergenic foods during ...
Food allergies are common and are associated with substantial morbidity; the only approved treatment is oral immunotherapy for peanut allergy. In this trial, we assessed whether omalizumab, a ...
Purpose: The pharmacology, efficacy, dosage, adverse events, and economics of omalizumab are discussed. Summary: Omalizumab, a recombinant DNA-derived humanized monoclonal antibody, binds to the Cε3 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results